All-oral antibiotic treatment for buruli ulcer: A report of four patients

PLoS Neglected Tropical Diseases

Volumn 4, Issue 11, 2010, Pages

  Gordon, Claire L ^a   Buntine, John A ^b,c   Hayman, John A ^d   Lavender, Caroline J ^e   Fyfe, Janet A M ^e   Hosking, Patrick ^b   Starr, Mike ^f   Johnson, Paul D R ^a,e  

^a AUSTIN HEALTH   (Australia)

^b BOX HILL HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^f ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; MOXIFLOXACIN; RIFAMPICIN; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; BACTERIUM ISOLATION; BURULI ULCER; CASE REPORT; CHILD; DRUG DOSE REDUCTION; EXCISION; FEMALE; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; MALE; MYCOBACTERIUM ULCERANS; NEUROLOGIC DISEASE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; SCHOOL CHILD; SKIN SURGERY; ULCER HEALING; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; BURULI ULCER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MYCOBACTERIUM ULCERANS;

EID: 78649795429     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000770     Document Type: Article

References (23)

1. Johnson PD, Stinear T, Small PL, Pluschke G, Merritt RW, et al. (2005) Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med 2: e108. doi:10.1371/journal.pmed.0020108.
2. Van der Werf TS, van der Graaf WT, Tappero JW, Asiedu K (1999) Mycobacterium ulcerans infection. Lancet 354: 1013-1018.
3. Lavender C J, Senanayake S N, Fyfe J A, Buntine J A, Globan M, et al. (2007) First case of Mycobacterium ulcerans disease (Bairnsdale or Buruli ulcer) acquired in New South Wales. Med J Aust 186: 62-63.
4. Francis G, Whitby M, Woods M (2006) Mycobacterium ulcerans infection: a rediscovered focus in the Capricorn Coast region of central Queensland. Med J Aust 185: 179-180.
5. Johnson PD, Veitch MG, Leslie DE, Flood PE, Hayman JA (1996) The emergence of Mycobacterium ulcerans infection near Melbourne. Med J Aust 164: 76-78.
6. Johnson PD, Hayman JA, Quek TY, Fyfe JA, Jenkin GA, et al. (2007) Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia. Med J Aust 186: 64-68.
7. Kibadi AK (2006) [Relapses after surgical treatment of Buruli ulcer in Africa]. Bull Soc Pathol Exot 99: 230-235.
8. Espey DK, Djomand G, Diomande I, Dosso M, Saki MZ, et al. (2002) A pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis 6: 60-65.
9. Fehr H, Egger M, Senn I (1994) Cotrimoxazole in the treatment of Mycobacterium ulcerans infection (Buruli ulcer) in west Africa. Trop Doct 24: 61-63.
10. Revill WD, Morrow RH, Pike MC, Ateng J (1973) A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet 2: 873-877.
11. Ji B, Chauffour A, Robert J, Lefrancois S, Jarlier V (2007) Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 51: 3737-3739.
12. Ji B, Lefrancois S, Robert J, Chauffour A, Truffot C, et al. (2006) In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother 50: 1921-1926.
13. Dega H, Bentoucha A, Robert J, Jarlier V, Grosset J (2002) Bactericidal activity of rifampinamikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother 46: 3193-3196.
14. Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, et al. (2001) Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 45: 3109-3112.
15. Dega H, Robert J, Bonnafous P, Jarlier V, Grosset J (2000) Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 44: 2367-2372.
16. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, et al. (2005) Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 49: 3182-3186.
17. World Health Orgnaization (2004) Provisional guidance on the role of specific antibiotics in the management of Mycbacterium ulcerans diseae (Buruliulcer). Geneva:WHO/CDS/CPE/GBUI.10, Available: http://www.who.int/buruli/information/antibiotics/en/index.html. Accessed 25 October 2010.
18. Chauty A, Ardant MF, Adeye A, Euverte H, Guedenon A, et al. (2007) Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 51: 4029-4035.
19. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, et al. (2010) Antimicrobial treatment for early, limited Mycobacterium ulcerans infection- a randomised controlled trial. Lancet 375: 664-672.
20. Jenkin GA, Smith M, Fairley M, Johnson PD (2002) Acute, oedematous Mycobacterium ulcerans infection in a farmer from far north Queensland. Med J Aust 176: 180-181.
21. O'Brien DP, Hughes AJ, Cheng AC, Henry MJ, Callan P, et al. (2007) Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust 186: 58-61.
22. O'Brien D P, Robson M E, Callan P P, McDonald A H (2009) Paradoxical'' immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust 191: 564-566.
23. Dossou AD, Sopoh GE, Johnson CR, Barogui YT, Affolabi D, et al. (2008) Management of Mycobacterium ulcerans infection in a pregnant woman in Benin using rifampicin and clarithromycin. Med J Aust 189: 532-533.